Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Zura Bio LimitedNASDAQ: ZURA
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 28.6% from a year ago
Common stock stood at $9K at the end of Q1 FY2026, up 28.6% from a year earlier and up 28.6% from the prior quarter.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +28.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 7K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- -91.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7K | +0.0% |
| FY2024 | 2024-12-31 | 7K | +75.0% |
| FY2023 | 2023-12-31 | 4K | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2022-03-31 | 139.38M | — |
Common Stock vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 common stock of $9K is the 8th highest of the 11 companies compared; the peer median is $18.5K.
- Its year-over-year change of +28.6% is the 5th highest of 10, against a peer median of +3.7%.
- Common stock amounts to 0.0% of total assets for ZURA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $64.69M | +179666.6% | +34.8% | 0.0% | |
| Mar 2026 | $291K | +36.0% | +1.0% | 0.1% | |
| Mar 2026 | $63K | +1.6% | +22.8% | 0.1% | |
| Mar 2026 | $28K | +3.7% | +1.2% | 0.0% | |
| Mar 2026 | $21K | +31.3% | +44.2% | 0.0% | |
| Mar 2026 | $16K | +100.0% | +58.7% | 0.0% | |
| Mar 2026 | $13K | +0.0% | +2.7% | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $9K | +28.6% | — | 0.0% |
| Mar 2026 | $6K | +0.0% | +14.5% | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $3K | +0.0% | +44.2% | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ZURA) | $18.5K | +3.7% | +22.8% | 0.0% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.